Iodixanol

From Wikipedia, the free encyclopedia


Iodixanol
Systematic (IUPAC) name
5 - [acetyl - [3 - [acetyl - [3,5-bis(2,3 - dihydroxypropylcarbamoyl) - 2,4,6 - triiodo - phenyl]amino] - 2 - hydroxy - propyl]amino] - N,N' - bis(2,3 - dihydroxypropyl) - 2,4,6 - triiodo - benzene - 1,3 - dicarboxamide
Identifiers
CAS number	92339-11-2
ATC code	?
PubChem	3724
Chemical data
Formula	C₃₅H₄₄I₆N₆O₁₅
Mol. mass	1550.191
Pharmacokinetic data
Bioavailability	?
Protein binding	Negligible
Metabolism	Excreted unchanged
Half life	2.1 hours
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Iodixanol, is a contrast agent, sold under the trade name Visipaque. Visipaque is commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. It is an iso-osmolar contrast agent, with an osmolality of 290 mOsm/kg H₂O, the same as blood. It is sold in 2 main concentrations 270 mgI/ml and 320 mgI/ml - hence the name Visipaque 270 or 320. It is sold in single dose units and a large 500ml plastic bottle for multi-dose dispensing

It was originally made by Nycomed, which then merged with Amersham which finally was bought by Jeff Immelt to become GE Healthcare. The majority of Visipaque is made in Cork, Ireland, with additional plants in China and Oslo. All Iodixanol bulk powder is made in Norway and shipped to the various plants for final manufacture.

For gradient density centrifugation, the product is known as OptiPrep.

A very similar product also manufactured by GE Healthcare is Omnipaque (Iohexol as the main drug substance).